Valuation: Arcus Biosciences, Inc.

Market Cap 3.44B 3.01B 2.78B 2.56B 4.82B 332B 4.93B 33.18B 13.05B 162B 12.93B 12.64B 559B P/E 2026 *
-7.45x
P/E 2027 * -8.12x
Enterprise Value 2.82B 2.47B 2.27B 2.1B 3.95B 272B 4.04B 27.19B 10.69B 133B 10.59B 10.36B 458B EV / Sales 2026 *
33.2x
EV / Sales 2027 * 34.2x
Free-Float
70.85%
Yield 2026 *
-
Yield 2027 * -
1 day+2.74%
1 week-5.36%
Current month-11.22%
1 month+12.59%
3 months+12.87%
6 months+25.55%
Current year+14.86%
1 week 25.68
Extreme 25.68
28.59
1 month 24.59
Extreme 24.59
31.74
Current year 18.52
Extreme 18.515
31.74
1 year 8.84
Extreme 8.84
31.74
3 years 6.5
Extreme 6.5
31.74
5 years 6.5
Extreme 6.5
49.1
10 years 6.3
Extreme 6.3
49.1
Manager TitleAgeSince
President 68 01/05/2015
Chief Executive Officer 67 01/05/2015
Director of Finance/CFO 53 01/08/2020
Director TitleAgeSince
Director/Board Member 62 10/12/2019
Chairman 67 01/12/2017
Director/Board Member 65 18/09/2017
Date Insider Type Main position Quantity % Market Cap.
10/7/26 Sell

Founder

-20,067 0.0160%
24/6/26 Sell

Founder

-6,431 0.0051%
11/6/26 Free

Director

22,600 0.0180%
Change 5-day change 1-year change 3-year change Capi.($)
+2.74%-5.36%+199.13%+38.44% 3.44B
-1.29%-3.11%-0.35%+2.64% 49.18B
+3.90%-0.39%+386.06%+588.97% 39.58B
-1.70%+4.46%+5.93%+61.54% 34.69B
-2.01%-0.76%+28.41%-8.52% 34.42B
+0.06%+0.34%+2.38%+34.47% 27.11B
+0.46%-3.49% - - 16.21B
-0.04%-0.09%+72.42%+116.45% 15.36B
+1.12%+1.91%+14.54%+15.44% 14.05B
0.00%+1.36%+18.43%-31.23% 13.02B
Average +0.32%-0.51%+80.77%+90.91% 24.71B
Weighted average by Cap. -0.01%-0.25%+81.23%+121.06%

Financials

2026 *2027 *
Net sales 85.06M 74.33M 68.59M 63.23M 119M 8.19B 122M 820M 322M 4.01B 319M 312M 13.81B 93.06M 81.32M 75.04M 69.17M 130M 8.96B 133M 897M 353M 4.39B 349M 342M 15.11B
Net income -456M -399M -368M -339M -639M -43.95B -654M -4.4B -1.73B -21.52B -1.71B -1.68B -74.1B -431M -376M -347M -320M -603M -41.46B -617M -4.15B -1.63B -20.31B -1.62B -1.58B -69.9B
Net Debt -621M -543M -501M -462M -870M -59.84B -890M -5.99B -2.36B -29.3B -2.33B -2.28B -101B -259M -227M -209M -193M -363M -24.98B -371M -2.5B -983M -12.23B -974M -953M -42.11B
Logo Arcus Biosciences, Inc.
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Employees
601
Date Price Change Volume
17/07/26 US$27.37 +2.74% 781,581
16/07/26 US$26.64 -4.93% 1,303,353
15/07/26 US$28.02 -1.09% 718,651
14/07/26 US$28.33 +0.93% 801,993
13/07/26 US$28.07 -2.94% 954,774
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
27.37USD
Average target price
35.75USD
Spread / Average Target
+30.62%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RCUS Stock